

REASSESSMENT OF THE UNDERLYING MECHANISMS THAT CONTRIBUTE TO THE NEUROLOGICAL DISORDERS LINKED TO LONG-TERM COVID-19

Anna Jaroszevska¹, Urantuya Battsengel¹, Zofia Zadorozna²

¹Department of Medical Informatics and Telemedicine, Medical University of Warsaw, Poland

²Students Research Club, Maria Skłodowska-Curie Medical Academy, Warsaw, Poland

KEYWORDS: COVID-19; long COVID-19; neurological

Disaster Emerg Med J 2024; 9(2): 129–130

We read with great interest the article by Graban and his colleagues [1] regarding the neurological effects of long COVID-19. A possible explanation for the neurological difficulties was proposed by the authors as cell fusion. Furthermore, the authors highlight that there is a considerable percentage of people feeling weariness and cognitive dysfunction, which includes lower attention span, short-term memory loss, and overall memory impairment. Moreover, recent scientific findings suggest that there are increasingly severe problems that follow these symptoms. There are considerable disparities in the intelligence quotient (IQ) between those who have been infected with SARS-CoV-2 and those who have not contracted the illness. Even a little illness can result in a decrease in IQ of around three points [2]. Nevertheless, it is important to note that most of these investigations were carried out in the first stage of the pandemic before the availability of vaccinations or antiviral medications and the permanence of these cognitive deficits is likewise uncertain. Research has previously demonstrated that certain individuals have structural brain abnormalities and other brain imaging abnormalities that are commensurate with the changes observed in the brains of typical individuals during

around seven years of ageing [3]. Despite the protective blood-brain barrier, inflammation can compromise its integrity, leading to the infiltration of proinflammatory cytokines. This phenomenon may help elucidate some symptoms observed following a COVID-19 infection [4]. One further thing that has been discovered is that people who have been infected with SARS-CoV-2 have abnormally low levels of cortisol, which is a hormone that is necessary for maintaining healthy cognitive functioning. The reduction in serotonin levels caused by COVID-19 infection and inflammation induced by type I interferon happens through three mechanisms: decreased absorption of tryptophan, the compound that precedes serotonin, in the intestines; increased activation of platelets and decreased platelet count, affecting serotonin storage; and increased serotonin turnover mediated by monoamine oxidase (MAO). Decreasing serotonin levels in the peripheral areas of the body obstructs the functioning of the vagus nerve, resulting in decreased reactions and memory in the hippocampus. These findings offer a potential rationale for the neurocognitive symptoms linked to the continuous existence of a virus in long COVID-19, which might also apply to other post-viral disorders. As

CORRESPONDING AUTHOR:

Urantuya Battsengel, Department of Medical Informatics and Telemedicine, Medical University of Warsaw, Litewska 14/16, 00–581 Warsaw, Poland
e-mail: e.julietta@yahoo.com

Received: 2.05.2024 Accepted: 7.05.2024 Early publication date: 13.06.2024

This article is available in open access under Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

a result, a reduction in peripheral serotonin hampers the activity of the vagus nerve, leading to a decrease in the functioning of the hippocampi and memory. These findings offer a potential explanation for the neurocognitive symptoms that are linked with viral persistence in long COVID-19 [5–8]. In addition to this, it can have a detrimental effect on memory and attention, as well as create persistent fatigue and alter normal sleep habits.

Article information and declarations

Author contributions

All authors contributed equally to the creation of the manuscript.

Acknowledgments

None.

Conflict of interest

All authors declare no conflict of interest.

Funding

This research received no external funding.

Supplementary material

None.

REFERENCES

1. Graban M, Pruc M, Chirico F, et al. Neurological implications of LONG-COVID-19 — current knowledge and the need for implementing remedies. *Disaster Emerg Med J.* 2024; 9(1): 60–61, doi: [10.5603/demj.99169](https://doi.org/10.5603/demj.99169).
2. Hampshire A, Azor A, Atchison C, et al. Cognition and memory after COVID-19 in a large community sample. *N Engl J Med.* 2024; 390(9): 806–818, doi: [10.1056/NEJMoa2311330](https://doi.org/10.1056/NEJMoa2311330), indexed in Pubmed: [38416429](https://pubmed.ncbi.nlm.nih.gov/38416429/).
3. Petersen M, Nägele FL, Mayer C, et al. Brain imaging and neuropsychological assessment of individuals recovered from a mild to moderate SARS-CoV-2 infection. *Proc Natl Acad Sci U S A.* 2023; 120(22): e2217232120, doi: [10.1073/pnas.2217232120](https://doi.org/10.1073/pnas.2217232120), indexed in Pubmed: [37220275](https://pubmed.ncbi.nlm.nih.gov/37220275/).
4. Greene C, Connolly R, Brennan D, et al. Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. *Nat Neurosci.* 2024; 27(3): 421–432 Erratum in: *Nat Neurosci.* 2024 Apr 16, doi: [10.1038/s41593-024-01576-9](https://doi.org/10.1038/s41593-024-01576-9), indexed in Pubmed: [38388736](https://pubmed.ncbi.nlm.nih.gov/38388736/).
5. Wong AC, Devason AS, Umana IC, et al. Serotonin reduction in post-acute sequelae of viral infection. *Cell.* 2023; 186(22): 4851–4867.e20, doi: [10.1016/j.cell.2023.09.013](https://doi.org/10.1016/j.cell.2023.09.013), indexed in Pubmed: [37848036](https://pubmed.ncbi.nlm.nih.gov/37848036/).
6. Dziedzic K, Pruc M, Kilic M, et al. Sex- and gender-specific differences in the inflammatory response to COVID-19: the role of the neutrophil-to-lymphocyte ratio. *Disaster Emerg Med J.* 2023; 8(4): 234–242, doi: [10.5603/demj.98191](https://doi.org/10.5603/demj.98191).
7. Harris E. Long COVID linked with viral persistence, serotonin decline. *JAMA.* 2023; 330(19): 1827, doi: [10.1001/jama.2023.21170](https://doi.org/10.1001/jama.2023.21170), indexed in Pubmed: [37910132](https://pubmed.ncbi.nlm.nih.gov/37910132/).
8. Dziedzic K, Rahnama-Hezavah M, Tomaszewska M, et al. Breaking down the clotting conundrum: analyzing the role of plasma tissue plasminogen activator in COVID-19 patients through a systematic review and meta-analysis. *Disaster Emerg Med J.* 2023; 8(4): 207–215, doi: [10.5603/demj.97097](https://doi.org/10.5603/demj.97097).